Comparison of Urobiome and Urine pH in Women with or without Overactive Bladder Symptoms Authors: Apichaya Klaikaew, Pisut Pongchaikul, Rujira Wattanayingcharoenchai, Komkrit Aimjirakul, Orawee Chinthakanan, Jittima Manonai Published: 2026 ABSTRACT AbstractObjectiveTo characterize the urobiome and urine pH in women with and without overactive bladder (OAB) symptoms.MethodsWe conducted a case-control study with 23 patients having OAB symptoms and 23 without OAB, based on overactive bladder symptom score questionnaires. Midstream urine samples were analyzed for pH and underwent 16S rDNA gene sequencing to identify the urobiome using diversity. Differential abundance analysis identified urobiome taxa associated with OAB symptoms.ResultsThe mean age of patients with OAB and those without OAB was comparable (63.60 ± 9.27 vs 62.26 ± 9.14, p = 0.62). There were no statistically significant differences in body mass index, parity, and menopausal status. Mean urine pH was also comparable (6.23 ± 1.04 vs. 6.17 ± 0.95, p = 0.84), though a higher percentage of OAB patients had acidic urine (73.91% vs. 65.22%, p = 0.53). While the overall urobiome showed no significant differences between groups, Corynebacterium spp. and Rothia spp. were more abundant in OAB patients.ConclusionPatients with overactive bladder had a higher abundance of certain urobiome bacteria but similar urine pH compared to those without symptoms.Keywords: overactive bladder, Urine pH, urinary urgency, urinary microbiome, urobiome Introduction Overactive bladder (OAB) is a specific form of lower urinary tract symptoms (LUTS) defined by a compelling urge to urinate, which can occur with or without involuntary urinary leakage in the absence of a urinary tract infection (UTI) or other identifiable causes.1 According to the International Continence Society (ICS), OAB is formally diagnosed based on symptoms of urinary urgency, usually accompanied by increased daytime frequency and/or nocturia, with or without urgency urinary incontinence, in the absence of a urinary tract infection or other obvious pathology.1 This condition is invariably linked to increased daytime frequency and nocturia. OAB, especially with urinary incontinence, has an adverse effect on patients’ quality of life (QoL). The etiology of OAB is still under investigation and is not well understood, with various factors potentially involved in its risk factors and pathological mechanisms. Currently, four main theories—neurogenic, myogenic, autonomous bladder, and afferent signaling—explain the pathophysiology of OAB.2 The neurogenic theory suggests a reduction in inhibitory neural impulses and an increase in afferent impulses from the bladder, resulting from damage to central inhibitory pathways or altered peripheral nerve sensitivity. The myogenic theory posits that urgency is caused by a hypersensitivity of the detrusor muscle to cholinergic stimulation, and bladder overactivity may result from alterations in phasic activity during the filling phase. Based on these theories, many treatments aim to achieve detrusor muscle relaxation to alleviate symptoms.3 However, some patients do not fully respond to standard antimuscarinic or β-adrenergic drugs, botulinum toxin, or other recommended treatments, highlighting the need to investigate additional potential causes and to define future research directions for OAB.3 Historically, the urinary tract was considered sterile; however, this long-standing belief has been disproven by advancements in molecular techniques, such as 16S rRNA gene sequencing.4–6 The term “urinary microbiome”, also known as “urobiome”, refers to the microbial community residing within the urinary tract. Emerging evidence suggests this community plays a crucial role in maintaining urogenital health and may be involved in the uncontrolled detrusor muscle contractions associated with urgency.7 Research has shown that the urobiome in women with OAB differs from that of healthy women.7–9 For instance, studies have identified common microbial genera, such as Lactobacillus, Gardnerella, and Prevotella, in the female urinary tract.10,11 Beyond these common genera, studies have also identified Corynebacterium, Actinobaculum, Aerococcus, and Gardnerella as taxa enriched in women with urgency symptoms compared to controls,7,12 suggesting that OAB-associated microbiome changes may occur at the species or genus level rather than through gross diversity shifts. The composition of the urinary microbiome is not static; it changes throughout the lifespan and is influenced by factors such as age, sex hormones, host genetics, and the interconnectedness of other bodily microbiomes, particularly the vaginal and gut microbiomes.13–15 Factors influencing microbial colonization also include environmental characteristics such as urine pH, oxygen tension, and nutrient availability.16 An acidic urine (pH < 7) can limit urothelial attachment, a key defense mechanism against uropathogens. Furthermore, an experimental study using a urine-alkalinizing diet reported improvements in OAB symptoms after 4 weeks of treatment.17 Hence, the urobiome and urine pH likely play important roles in urinary urgency, a key symptom of OAB.8,17 The objective of this project was to compare urobiome characteristics and urine pH in women with and without OAB symptoms. By doing so, there is tremendous potential to improve the diagnosis, evaluation, and treatment of individuals affected by OAB. Materials and Methods Study Population The Institutional Review Board approved the protocol for this case-control study (COA MURA2021/1059). Between June 2022 and August 2022, consecutive women who had been visiting the urogynecology clinic with at least one pelvic floor symptom were recruited and divided into two groups: those with and without OAB symptoms. The term “at least one pelvic floor symptom” refers to the presence of any lower urinary tract or pelvic floor symptom prompting clinic attendance, including urinary urgency, increased daytime frequency, nocturia, stress urinary incontinence, or pelvic pain. The control group was defined as women whose OABSS total score was below 3 or whose urgency subscore was below 2, indicating the absence of clinically significant OAB symptoms. The inclusion criteria were women aged 18 or older who communicated fluently in Thai. Women with urinary tract infections diagnosed by urine dipstick, antibiotic usage within the previous week, pelvic organ prolapse (POP) worse than stage II, and local estrogen treatment use within the last three months were excluded from this study. The Thai-validated Overactive Bladder Symptom Score (OABSS) was administered to potential participants. The OAB group was defined as participants with a score of at least 3 and an urgency score of at least 2. The control group was identified as free of the OAB symptoms based on the OABSS score. History taking and pelvic examination were performed by the principal investigator (AK) in all participants. Pelvic organ prolapse severity was assessed and classified using the Pelvic Organ Prolapse Quantification system (POP-Q), and vaginal atrophy was evaluated simultaneously through direct inspection. All participants provided written approval and expressed their willingness to participate. Urine Collection In this study, clean-catch midstream urine (MSU) collection was employed to capture the lower urinary tract microbiome, including bacteria residing in both the bladder and urethra, providing a comprehensive and non-invasive assessment of the urobiome compared to catheterization.7 A total volume of 20 mL of midstream urine was collected from all participants using a standard clinical protocol. To minimize contamination, the participant was instructed to clean the labia with tap water before voiding, then deliver a first-void urine sample and squeeze off. Then, an MSU sample was kept in a sterile cup.5 Urine specimens were tested using a dipstick to exclude urinary tract infections. The urine was divided into two parts. The first 10 mL of the sample was submitted to the central laboratory for urinalysis to determine the urine pH. The remaining 10 mL of urine were immediately transported to the laboratory via the sterile container, which was stored at 4 °C. After preserving the Urine with Urine stabilizing buffer (Zymo Research, Irvine, CA) with an optimal ratio (recommended by the manufacturer), the urine was centrifuged at 3500 x g for 4 minutes at 4-degree °C. Later, the supernatant was discarded, and the pellet was stored at −80 °C until further use. Urine Analysis and pH Test The first 10 mL of urine was taken to the laboratory of our institute for urinalysis. The urine pH was determined by qualified staff at the hospital laboratory via urinalysis. The essential steps involve spinning the urine sample at 3000 rpm for 3 minutes. After centrifugation, the supernatant was discarded, and the sediment was resuspended in the few remaining drops of the supernatant. A drop of this was placed on a slide, a coverslip was applied, and the slide was examined under a microscope. The reagent-impregnated strips provide information on urine pH, protein, glucose, ketones, and other substances. Urine pH range was 5–9. Urobiome Analysis DNA extraction and 16S ribosomal RNA gene sequencing were performed by Zymo Research service. Briefly, DNA extraction was performed using the ZymoBIOMICS DNA Miniprep Kit (Zymo Research, Irvine, CA), following the manufacturer’s manual. Library preparation was conducted using the Quick-16S™ NGS Library Prep Kit (Zymo Research, Irvine, CA) with 16S primers that cover the V3-V4 region of the 16S ribosomal RNA gene. The final pooled library was quantified using TapeStation (Agilent Technologies, Santa Clara, CA) and Qubit (ThermoFisher Scientific, Waltham, MA). The sequencing was performed on an Illumina MiSeq with a v3 reagent kit and 10% PhiX spike-in. For the bioinformatics Analysis, raw reads were qualified using FastQC. The analysis for unique amplicon sequence variants (ASV) and the removal of errors and chimeric sequences were done using the DADA2 pipeline. Taxonomy assignment and alpha diversity (richness, Shannon, and Simpson) were evaluated using QIIME 2 software. The Wilcoxon rank-sum test was used to evaluate differences in alpha diversity. For Beta-diversity, the Bray-Curtis dissimilarity index was calculated to compare microbial composition between samples. Linear discriminant analysis effect size (LEfSe) was used to investigate microbial biomarkers at the genus level between groups. The threshold value of the logarithmic Linear Discriminant Analysis (LDA) score for discriminative features was 2.0. DNA sequences used in this study were deposited onto GENBANK (Accession No. PRJNA970190). Statistical Analyses Continuous variables were described as means and standard deviations (SD) or medians and interquartile ranges (IQR). T-tests and Mann–Whitney U-tests were used to evaluate differences in baseline characteristics between cohorts, with the Pearson Chi-square test and Fisher’s exact test employed for categorical variables. Statistical tests were based on the probability of two tails. The odds ratio presented the association between a specific microbiome and OAB symptoms. Moreover, when the P-value is less than 0.05, the result is considered significant. The correlation between urine pH and urine microbiome was analyzed using the correlation coefficient. Sample Size Estimation The sample size estimation was calculated based on the prevalence of the microbiome in the urinary urgency and non-urinary urgency groups from a previous study.12 Two independent proportions with an alpha error of 5%, a beta error of 20%, and 30% data loss were calculated. The sample comprised 23 cases per group, for a total of 46 participants. Results Demographic Data A total of 48 patients who had visited the urogynecology clinic between June and August 2022 were enrolled in this study. Two patients were excluded due to persistent estrogen use and a POP-Q score worse than stage II (Figure 1). Demographics and baseline characteristics are shown in Table 1. The mean age of patients with OAB and those without OAB was not different (63.60 ± 9.27 vs 62.26 ± 9.14; p = 0.62). Most of them were parous and postmenopausal. OABSS score was significantly higher in the OAB group (7.52 vs 0.96, p < 0.0001). Body mass index (BMI) was slightly higher in the OAB group compared with the control group (25.81+-3.77 vs 24.01+-3.89, p = 0.12). Individuals with OAB symptoms had an insignificantly higher prevalence of type 2 Diabetes Mellitus (p = 0.51). Other demographic data related to obstetric and gynecologic history did not differ significantly between the two groups. On physical examination, the number of patients with vaginal atrophy was comparable between groups (N = 21; 91.30% in each group; p = 1.00). Flow diagram of study protocol. Table 1Demographics and Baseline Characteristics (N = 46)CharacteristicOAB Group (N=23)Control Group (N=23)P valueAge (Mean ± SD)63.60 ± 9.2762.26 ± 9.140.62BMI (Mean ± SD)25.18 ± 3.7724.01 ± 3.890.12Underlying (N,%) Hypertension9 (39.13%)8 (34.78%)0.76 Diabetes Mellitus7 (30.43%)5 (8.70%)0.51Parity (N,%) Nulliparous4 (17.40%)4 (17.40%)1.00 Multiparous19 (82.60%)19 (82.60%)1.00Menopause (N,%)21 (91.30%)21 (91.30%)1.00Vaginal atrophy (N,%)21 (91.30%)21 (91.30%)1.00 Demographics and Baseline Characteristics (N = 46) Urine pH The average urine pH was slightly higher (indicating greater alkalosis) in the OAB group than in the control group (OAB vs. Control; 6.23 vs. 6.17). The difference between the two groups was not statistically significant (p = 0.84). However, there was a higher proportion of acidic urine (pH < 7) among patients with OAB symptoms (73.91% vs. 65.22%, p = 0.53), as shown in Table 2. Further analysis revealed that Kocuria spp. was associated with lower urine pH (r = −0.12, p = 0.042), while Corynebacteriaceae was associated with higher urine pH (r = 0.15, p = 0.026). Table 2Urine pH (N = 46)OAB (N=23)Control (N=23)P valueUrine pH [Mean ± SD]6.23 ± 1.046.17 ± 0.950.84Urine [N (%)] Acidosis17 (73.91%)15 (65.22%)0.53 Neutral2 (8.7%)6 (26.09%)0.12 Alkalosis4 (17.39%)2 (8.70%)0.38 Urine pH (N = 46) Urobiome Urotype was defined as the predominant genus (relative abundance >50%) present in urine samples from all patients. On the contrary, if none of the genus reaches a relative abundance of 50%, the urotype was regarded as “diverse”. The relative bacterial abundance at the genus level for each patient is shown in Figure 2. The indices of bacterial alpha diversity, measured by richness, Shannon’s index, and Simpson’s index, are shown in Figure 3. We found that alpha diversity in the OAB group was lower than in the control group, although the difference was not statistically significant. Relative bacterial abundance of each patient at the genus level. Alpha diversity of urobiome ((A), richness; (B), Shannon’s index; (C), Simpson’s index) and Beta diversity of urobiome (D) in the case and control groups. For beta diversity, principal coordinate analysis (PCoA) was performed to compare urinary microbiota composition between the two groups based on Bray–Curtis distance (Figure 3). There was no statistically significant difference in bacterial composition between the OAB and control groups. LEfSe analysis for biomarker identified that species composition of the two groups differed significantly; a total of six bacterial taxa were evidently enriched in patients with OAB symptoms, and a total of five taxa were enriched in patients in control group (Figure 4A). Significantly different urobiome in OAB group by LDA (A); Percentage of urobiome present in the OAB and Control groups (B). **p<0.01; *p<0.05; †p<0.1; n.s., nonsignificant (Fisher’s exact test, two-sided). Haldene correction applied when cell = 0. Abbreviation: LDA, linear discriminant analysis. Interestingly, only odds ratio of Rothia amarae and Kocuria rhizophila was statistically significant (Table 3; Figure 4B). Kocuria rhizophila (detected via the combined classifier assignment s__rhizophila-salsicia) was found exclusively in OAB patients (21.7% vs 0% in controls; OR = 14.0, 95% CI: 0.73–269, Fisher’s p = 0.049). The complete absence of this taxon in all 23 controls is notable. Table 3Odds Ratio of Urobiome Species-Specific in OAB GroupUrobiome SpeciesOdd Ratio95% CICorynebacterium coyleae-pilbarense5.01.04–30.2Kytococcus schroeteri10.850.55–214.15Kocuria rhizophila1.570.24–10.4Rothia amarae16.921.94–147.77Atopobium vaginae7.760.85–70.75Lactobacillus gallinarum10.850.55–214.15 Odds Ratio of Urobiome Species-Specific in OAB Group Discussion The recent development and application of 16S ribosomal RNA (rRNA) gene sequencing technology has revealed that the “healthy” bladder is not sterile, challenging a long-held paradigm.6,7,18,19 This discovery has led to an increased investigation into the role of the urinary microbiome, also known as the urobiome, in the development of urinary symptoms and diseases.4,9 Prior studies have found that women with urgency urinary incontinence and OAB have different bacterial urine groups from healthy controls.8–11,13,20 In this case-control study, we identified and characterized the differences in urobiomes between women with and without OAB symptoms using high-throughput sequencing of the bacterial 16S rRNA gene. We found several bacteria, including Corynebacterium coyleae, Kytococcus schroeteri, Kocuria rhizophila, Rothia amarae, Atopobium vaginae, and Lactobacillus gallinarum, to be present in women with OAB symptoms. We found no significant difference in alpha and beta diversity between the groups. An interesting trend was noted, however, with Kocuria spp. associated with low urine pH and Corynebacteriaceae associated with high urine pH. These findings suggest a potential role for the urine microbiome and urine pH in the manifestation of urinary symptoms. We investigated differences in the urine microbiome between patients with OAB symptoms and those without, including alpha and beta diversity and the abundance of specific bacteria. Prior studies have linked a loss of microbial diversity, or dysbiosis, with specific urinary symptoms or conditions.4,9 For example, Karstens et al (2016) identified statistically significant differences in the relative abundance of specific microbes in urine from women with UUI, finding that lower microbial diversity was associated with increased symptom severity.9 Similarly, another study found lower bacterial richness and diversity in the urine samples of women with UUI.4 However, although our findings showed a trend toward lower bacterial diversity in the OAB group, they did not support this hypothesis, consistent with other studies that found no significant changes in diversity.12,13 Previous studies comparing urine and vaginal bacteria in individuals with and without UUI found no differences in diversity but noted differences in Lactobacillus species between the two groups.13,21 This finding suggests that the key distinction might not be in the overall diversity of the urinary microbiome but rather in the specific types of bacteria present. It is also worth noting that differences in urine collection methods—midstream voiding versus catheterization —can influence diversity metrics.19,20,22 Importantly, our use of clean-catch midstream urine, rather than transurethral catheterization as employed by Wu et al4 and Pearce et al,12 captures bacteria residing across both the bladder and urethra simultaneously, reflecting a broader ecological snapshot of the lower urinary tract microbiome. While catheterized specimens more selectively reflect bladder content, midstream collection is a non-invasive and clinically practical alternative, and both methods have been employed in the urobiome literature with distinct trade-offs.19,22 Our identification of specific enriched taxa in OAB patients aligns with and extends prior reports. Curtiss et al (2017) found that Corynebacterium was among the most commonly isolated genera (37% of samples), with Lactobacillus significantly reduced in OAB patients compared to controls,7 a finding consistent with our observation of Corynebacterium enrichment in OAB. Similarly, Pearce et al (2014) identified Corynebacterium coyleae as more frequently isolated from women with urgency urinary incontinence (UUI), supporting the potential pathogenic role of this genus in lower urinary tract dysfunction.12 Wu et al (2017) further reported enrichment of Proteus and Aerococcus in OAB patients using catheterized specimens, while Lactobacillus and Prevotella were reduced4 while Kaya et al (2025) found Staphylococcus epidermidis enriched in OAB patients, with Lactobacillus more abundant in controls.20 Both studies are not similar to our cohort, which may reflect differences in collection method, population demographics, or disease severity. Our findings of Rothia amarae and Kocuria rhizophila as significantly associated taxa have not been prominently reported in prior studies, potentially reflecting population-specific or methodological differences, and warrant confirmation in larger cohorts. While many studies have reported on the relationship between the urinary microbiome and OAB, the roles of specific bacteria have not yet been fully explored.8,9,12,13,20 In our study, we performed biomarker analysis and calculation of odds ratio for each individual bacterial species obtained from biomarker analysis. Of the six species identified by LEfSe analysis, Rothia amarae and Kocuria rhizophila had significant odds ratios, suggesting a stronger association with OAB. Rothia species are members of the Micrococcaceae family within Actinobacteria and have been identified in the urinary microbiome of patients with lower urinary tract symptoms, though their functional role remains unclear. The presence of Rothia spp., which are typically part of the oral and respiratory microflora, has been reported in patients with recurrent cystitis, further supporting the idea that OAB symptoms may be associated with bacteria not detected by standard tests.23–25 This finding highlights the need for advanced diagnostic techniques. Kocuria species are Gram-positive, catalase-positive, coagulase-negative cocci belonging to the family Micrococcaceae. Originally reclassified from Micrococcus in 1995 based on 16S rRNA phylogenetics, Kocuria inhabits human skin, oral mucosa, and oropharynx.26 The exclusive detection of K. rhizophila in OAB urine is intriguing and, to our knowledge, has not been reported in prior urinary microbiome studies. Given its capacity to form biofilms on medical devices and its documented role in catheter-associated infections, one speculative mechanism involves mucosal biofilm colonization of the bladder epithelium in OAB patients, potentially facilitated by altered urothelial barrier integrity. Whether its presence is causally related to OAB pathogenesis or reflects secondary colonization remains unknown. The odds ratio of Corynebacterium coyleae-pilbarense nearly met the significant level. Of the two candidate species, C. coyleae has the stronger existing literature linking it to the urinary tract. First described in 1997 by Funke et al, C. coyleae is a commensal of skin, urethra, and genital tract mucosa.27 Sokol-Leszczynska et al evaluated 39 C. coyleae urine isolates and found that, although most (72%) were contamination or colonization, the species was the sole pathogen in 6 confirmed UTI cases, predominantly in women.28 It was concluded that C. coyleae could be considered an emerging pathogen in complicated urinary tract infections. Corynebacterium is known to be capable of invading urothelial cells and persisting, potentially leading to chronic, low-grade infections not detectable by conventional culture.15,22 These intracellular bacterial communities can irritate the bladder lining, potentially causing OAB symptoms.11,29 Factors influencing microbial colonization also include environmental characteristics, such as urine pH, oxygen tension, and nutrient availability.16 Changes in ion equilibrium can increase the permeability of the bladder lining, stimulating lower urinary tract symptoms.17,30 While some studies suggest acidic urine is associated with OAB symptoms due to enhanced access to nerve and muscle cells of the detrusor,31 our study found no significant difference in overall urine pH between the groups. Nevertheless, a higher proportion of OAB patients had acidic urine, while a higher proportion of the control group had neutralized urine. This finding is supported by other research where alkalinizing urine improved patient QoL by significantly reducing frequency, urgency, and nocturia.32,33 Our study also found that Kocuria spp. was more common in patients with urine acidosis, while Corynebacterium spp. was more prevalent in patients with alkaline urine. This finding suggests that the presence of specific bacteria may be more influential in the onset of OAB symptoms than pH alone, as pathogenic bacteria can thrive in both acidic and alkaline environments. The strengths of our study include being the first in Southeast Asia to investigate urobiome characteristics and urine pH in women with and without OAB, which may reveal unique endemic pathogenic bacteria. The parallel demographic characteristics of the two groups also helped exclude potential confounding factors. However, the study has limitations: the one-time sample collection makes it difficult to establish a cause-and-effect relationship, the standard urine culture was not applied to eliminate UTIs, and the small sample size warrants caution in generalizing the results. Additional large-scale prospective studies are required to fully explain the vital role of the urinary microbiome in OAB pathophysiology. Regarding clinical implications, our findings emphasize that bacteria in urine that are not detected by conventional tests may be associated with OAB symptoms regardless of urine pH. An understanding of the aberrant urinary microbiome has substantial implications for explaining pathophysiology and broadening treatment options. Our results also suggest a need to move beyond standard diagnostic methods better to characterize the urinary microbiome of patients with OAB. The finding that specific bacteria are associated with symptoms, regardless of urine pH, opens the door for a paradigm shift in treatment strategies. Future treatments for OAB may therefore involve not only antimuscarinics and beta-adrenergic agonists, but also targeted therapies such as probiotics and novel drug-delivery systems that modulate the urinary microbiome. However, they could also include targeted therapies that modulate the microbiome, such as the use of probiotics, or novel drug delivery systems designed to address these specific microbial imbalances. A more comprehensive, functional understanding of the urobiome is essential for developing personalized and effective therapies for individuals affected by OAB. Conclusion In conclusion, our study confirms the modern understanding that the bladder is not sterile and that the urinary microbiome plays a role in bladder health. We found that urobiome composition differed between women with OAB symptoms and the control group, with a higher prevalence of specific bacteria, including Corynebacterium coyleae-pilbarense, Rothia amarae, and Kocuria rhizophila, in the OAB cohort. While we did not find a significant difference in overall microbial diversity or urine pH between the two groups, the presence of these specific microbes suggests that the type of bacteria, rather than overall microbial richness, is a key factor in OAB pathophysiology. These findings support the notion that OAB symptoms may be linked to low-grade, persistent bacterial communities that are not detected by conventional urine cultures. Funding Statement Faculty of Medicine Ramathibodi Hospital. Clinical Trial Registration This study does not require registration because it is case-control and observational. Participants were recruited and divided into two groups based on their OAB symptom scores; no intervention was performed. Researchers observed participants and their outcomes without interfering with their treatment or lifestyle. Data Sharing Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Ethics of Approval Statement The study was approved by the Human Research Ethics Committee, Faculty of Medicine Ramathibodi Hospital, Mahidol University (protocol number: MURA2021/1059). This study was conducted in accordance with the Declaration of Helsinki. Patient Consent Statement Written informed consent has been obtained from the participating patients prior to study entry. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure Dr Orawee Chinthakanan reports Honoraria from Speakers, outside the submitted work. The authors report no conflicts of interest in this work. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.